Uso do Canabidiol para o tratamento da epilepsia.

Abstract

Epilepsy is considered a neurological disorder that affects people of any age group, it is estimated that about 65 million people worldwide live with this disease, according to the World Health Organization (WHO). Cannabis sativa, or popularly known as marijuana, has therapeutic applications and its use for medical purposes has been increasingly studied. Preclinical research demonstrates that Cannabidiol (CBD) has several therapeutic effects, such as anticonvulsant, anti-inflammatory, neuroprotective, antipsychotic, antitumor and anxiolytic activity. Therefore, this research aims to review the therapeutic potential of cannabidiol for the treatment of epilepsy. The present study is an integrative review, using data available on the internet in the VHL, LILACS and Scielo databases. For the search, systematized descriptors were used through Boolean operators with the following strategy: “Epilepsy AND Cannabidiol”. This research included original or complete review articles on the subject, published in the period from 2013 to 2023, only materials in Portuguese and studies that did not investigate the proposed subject, articles with paid access, temporal margin greater than ten years and lack of correlation with the theme. From this research, 33 results were found, which consequently resulted in an evaluation, in which 05 studies were selected for the production of this work. The use of CBD as an adjuvant therapy proves to be an alternative where it provides a reduction in crises, better conditions and quality of life for patients, however it is not yet an eligible drug to be incorporated into the SUS. Despite the promising potential of CBD, there are many therapeutic problems surrounding its use, such as the knowledge of its pharmacodynamics and its use in crises. Also about the continuous use for certain syndromes, occurrence of drug interactions, risk of adverse effects and lack of standardized therapeutic guidelines for its clinical use.